GRAL vs UNH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRAL exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical operational instability. While the company maintains an exceptionally high current ratio (11.97) and low debt, these are offset by catastrophic profit margins (-277.46%) and a bearish technical trend. Despite consistent earnings beats relative to low expectations and a 'Buy' analyst consensus, heavy insider selling ($95.49M) suggests a lack of confidence from leadership.
UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.
Compare Another Pair
Related Comparisons
GRAL vs UNH: Head-to-Head Comparison
This page compares GRAIL, Inc. (GRAL) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.